GMTXDisc Medicine, Inc.

Nasdaq geminitherapeutics.com


$ 33.26 $ 2.00 (6.4 %)    

Wednesday, 22-May-2024 15:59:44 EDT
QQQ $ 454.82 $ -0.33 (-0.07 %)
DIA $ 398.57 $ -2.09 (-0.52 %)
SPY $ 530.36 $ -1.56 (-0.29 %)
TLT $ 91.26 $ 0.43 (0.47 %)
GLD $ 225.37 $ -4.09 (-1.82 %)
$ 31.26
$ 31.17
$ 0.00 x 0
$ 0.00 x 0
$ 31.17 - $ 33.47
$ 25.60 - $ 77.60
401,749
na
775.56M
$ 0.58
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-21-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-06-2022 03-31-2022 10-Q
10 03-10-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-29-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-minerva-surgical-shares-are-trading-higher-by-166-here-are-26-stocks-moving-premarket

Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares rose 166% to $0.4327 in pre-market trading after the company reported a...

 gemini-therapeutics-merger-company-disc-medicine-granted-fda-orphan-designation-for-erythropoietic-protoporphyria-treatment

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=916222

 why-invitae-climbed-around-279-here-are-98-biggest-movers-from-yesterday

Gainers Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 ...

 biotech-daily-cancer-causing-impurities-in-mercks-diabetic-drug-vir-bio-gsk-shun-fda-submission-plans-for-covid-19-treatment-aethlons-monkeypox-trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

 gemini-therapeutics-and-disc-medicine-announce-merger-agreement

Merger to create NASDAQ-listed, clinical-stage biopharmaceutical company focused on advancing Disc Medicine’s portfolio of he...

 the-daily-biotech-pulse-pfizer-biontech-covid-19-booster-data-in-kids-regenerons-covid-19-therapy-decision-pushed-protagonists-rusfertide-breakthrough-tag-update-and-more

Here's a roundup of top developments in the biotech space over the last 24 hours:

 gemini-therapeutics-director-michael-leonard-buys-955k-shares-at-average-price-of-140share

-SEC Filing

 benzingas-top-ratings-upgrades-downgrades-for-march-11-2022

Upgrades

 10-biggest-price-target-changes-for-friday

Needham cut the price target on OppFi Inc. (NYSE: OPFI) from $10 to $4.5. OppFi shares rose 5.3% to $3.20 in pre-market tra...

 hc-wainwright--co-downgrades-gemini-therapeutics-to-neutral-lowers-price-target-to-2

HC Wainwright & Co. analyst Andrew Fein downgrades Gemini Therapeutics (NASDAQ:GMTX) from Buy to Neutral and lowers the ...

 what-5-analyst-ratings-have-to-say-about-gemini-therapeutics

Within the last quarter, Gemini Therapeutics (NASDAQ:GMTX) has observed the following analyst ratings:

 benzingas-top-ratings-upgrades-downgrades-for-march-3-2022

Upgrades

 10-biggest-price-target-changes-for-thursday

Piper Sandler cut the price target on Bright Health Group, Inc. (NYSE: BHG) from $10 to $5. Bright Health shares rose 3.2% ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION